2021 eastern region candidates
Candidates are listed alphabetically by last name.
Assistant Professor, Sultan Qaboos University, Oman
I am a physician scientist who did a PhD in translational cancer proteomic research. My PhD work was in the proteomic profile in sera of metastatic and non-metastatic breast cancer. I worked with a competent team in the field and was able to construct a milti-marker model that can predict breast cancer metastasis (work is under review). Oman has no proteomic team. Therefore, I committed myself to establish one. I started conducting seminars on basics and advances in proteomics in medicine. We were able to attract interested people into a team that work currently in two big projects in Acute Myeloid leukemia and early onset colorectal cancer.
I am working actively with Prof Sanjeeva (an active of member in HUPO) in one of these 2 projects aiming to initiate a capacity building for proteomics in Oman.
My vision is to establish a proteomic society in Oman that serves a collaborative research work with proteomic experts in the region and globally.
Being elected for HUPO councils will help me build network with experts, share ideas and subsequently encourage Arab physicians/ scientists to work together to make this aim successful.
Professor, Seoul National University, South Korea
My current position as a professor is in the Department of Biochemistry, College of Veterinary Medicine, Seoul National University, South Korea. After attaining my PhD at Ohio State University, USA, my Post-Doc training was done at the BIDMC Genomics center, Harvard Medical School (2001-2003), where my proteomics research begun. Then, as a professor at Kyungpook National University, Korea, from 2003 to 2011, my proteomics research was further developed. I have served as a Secretary General of Korean Human Proteome Organization (KHUPO) (2012-2013), 10th and 11th President of KHUPO (2018-2019; 2020-
2021), council member of AOHUPO (2014-2022), and council member of HUPO (2018-2020). Also currently serving as PI of Chromosome #9 team in the international chromosomebased human proteome project (C-HPP). My current research includes the development of cancer biomarkers through glycoproteomics using LC-ms/ms-based mass spectrometry. One of the main approaches for the biomarker development is based on comparative medicine between humans and companion animals in similar environments. My lab validates various biomarkers by MRM and further develops In vitro diagnostic–Multivariate index assays (IVDMIA) for disease diagnosis and precision medicine. I have published more than150 papers in the area of proteomics and its application to cancer and other biology, in journals including MCP, Sci Transl Med, PNAS, and JPR. One of the main reasons why I aspire to and am wellsuited for a position on the HUPO council is that, as the chair of the 10th AOHUPO organizing committee, I want to sincerely serve in a good international position. As KHUPO president, I am hosting the 10th AOHUPO 2021 conference in Busan, Korea. The conference was originally scheduled to be held in 2020, however due to the COVID-19 pandemic, it was postponed to 2021 summer. This great experience of organizing AOHUPO 2021 congressdefinitely endow with me to be well prepared as a HUPO council in various aspects of international conference organization.
Chief, National Cancer Center, Japan
My research interest has been focusing on the clinical applications of proteomics. As a scientist with medical backgrounds, I challenged cancer biomarker development for personalized medicine. I value collaborations with physicians and pathologists, and trained more than 20 young doctors in my laboratory. We have been participating in the HUPO World Congress since its first meeting in Versailles, Paris, 2002, and every year, we presented our research results. If elected to the council member, I would advocate for promoting translational cancer research. Clinical questions at the bedside should facilitate clinical proteomics, and the research outcome of cancer proteomics have been expected to revolutionize clinical practice. To conduct cancer proteomics, I crated unique proteomics modalities, cancer models, and a public biobank. The mutual communication among the researchers in different field is essentially important to conduct translational cancer research, and the researchers who have backgrounds in multiple fields can promote such communications. I believe that my experience will allow me to contribute HUPO.
Professor, University of New South Wales, Australia
Marc Wilkins developed the concept of the proteome and coined the term. He has been a researcher in the field of proteomics for 25 years and has authored more than 210 publications. He served as a senior editor for PROTEOMICS over 10 years and, prior to that, as an editorial board member of ELECTROPHORESIS.
Marc has served HUPO over an extended period. He has been elected to and served on the Council of HUPO for four previous terms. For HUPO2010 in Sydney, Australia, he was the program chair and a co-convenor of the congress. Subsequently, Marc served on the international program committees of HUPO2013 (Yokohama) and HUPO2017 (Dublin). Recently, he served on the organising committee of the HUPO2019 congress, held in Adelaide, Australia.
In Australia, since 2015, Marc has served on the Management Committee of the Australasian Proteomics Society. Since 2015 he has also served on the organising committee of the society’s annual conference (the Lorne proteomics congress).
Marc is currently a Professor at the University of New South Wales, in Sydney. His research interests are in the function of protein methylation in the proteome and in how protein post-translational modifications modulate the interactions of proteins in global networks. The latter is being investigated with crosslinking mass spectrometry. He was recently awarded a Doctor of Science (D. Sc) for his contributions to the field of proteomics and protein post-translational modifications.